img_hblbg.jpg
logo.jpg
img_hbrbg.jpg

Milestones

  • January -
     
    Ipca was awarded by 'Indian Drug Manufacturers Association (IDMA) Best Formulation Patent (2014-15)' for its formulation patent of Hydroxychloroquine and its combinations in treatment of Diabetes Mellitus at 54th IDMA annual day celebration held on 23rd January 2016.
     
    Clinical Study entitled "Efficacy and Safety of Fixed Dose Combination of Atorvastatin and Hydroxychloroquine: A Randomized, double-blind comparison with Atorvastatin Alone among Indian Patients with Dyslipidemia" is published in Current Medical Research and opinion. With this publication, Ipca's total number of publications (Including clinical and preclinical studies) has reached 37.
     
    Clinical trial entitled "Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring" published in renowned Journal of the American College of Cardiology. With this publication, Ipca's total number of publications has reached an impressive number 38!
    Journal of the American College of Cardiology is best read, one of the most highly cited and influential cardiovascular journal worldwide, with an international reputation for excellence and a notable impact factor of 16.503. Dr. Franz Messerli, a leading authority on hypertension management is a co-author for this paper.
    March -
     
    Ipca Sports Club wins the E-Merck Pharmaceutical Shield Cricket Tournament in the E-Division against Kotak Mahindra Sports Club.
    April -
     
    Ipca Laboratories wins the 'Clinical Trial result of the year' at the first annual CARE Award held at Boston, USA on 27th April 2016.
    Both the entries, 'Efficacy and Safety of Fixed-Dose Combination of Atorvastatin and Hydroxychloroquine' and, 'Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as assessed by 24-h Ambulatory Blood Pressure Monitoring' have been nominated for this award.
    Ipca was the only Indian company to get shortlisted as finalist for this prestigious awards and the only company with two projects being shortlisted in single category.
    July -
     
    Zerodol was awarded as "Brand of the Year" by CIMS on 30th July 2016.
    November -
     
    Ipca Laboratories has been conferred with "Intellectual Property (IP) Excellence Award 2016" for adopting "The Best Practices in IP Intelligence" in a function organized in Mumbai on November 28th, 2016.
    The award has been granted by Questel-de Sciene Infoware in recognition of Ipca's IP intelligence analytics capabilities in an event chaired by diversified IP professionals from Leading Pharma and Biotech companies, Automobiles industry, Infrastructure, Healthcare, Textiles and Engineering Sector.
    Questel-de Sciene Infoware is a French company which provides comprehensive suite of web-based services for productivity and collaboration dedicated to intellectual property. Questel has conducted India wide online survey and selected Ipca as one of the leading companies for following best practices in IP intelligence.
    December -
     
    Ipca's Ratlam manufacturing Unit won 1st prize in National Energy Conservation Award 2016. This ceremony was hosted in Delhi on 14th December 2016 and the award was presented by Mr. Piyush Goyal, the Minister of State with Independent Charge for Power, Coal, New and Renewable Energy and Mines in the Government of India.
    Prior to this, Ipca's Ratlam Unit won 3rd prize and 2nd prize in the years 2010 and 2007 respectively.
    National energy conservation day is celebrated every year by the people all over the India on 14th of December. The Energy Conservation Act in India was executed by the Bureau of Energy Efficiency (BEE) in the year 2001. The Bureau of Energy Efficiency is a constitutional body which comes under Government of India and helps in the development of policies and strategies in order to reduce in the energy use.
Copyright © Ipca Laboratories Ltd. 2012. All Rights Reserved.